Effectiveness of the PPARγ agonist, GW570, in liver fibrosis

Author： Yang Liu   Stimpson Stephen   Chen Lihong   Wallace Harrington W.   Rockey Don  

Publisher： Springer Publishing Company

ISSN： 1023-3830

Source： Inflammation Research, Vol.59, Iss.12, 2010-12, pp. : 1061-1071

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR-γ Agonist

By Su Mingzhi   Cao Jiafu   Huang Jin   Liu Sen   Im Dong Soon   Yoo Jin-Wook   Jung Jee H.  

Marine Drugs, Vol. 15, Iss. 1, 2017-01 ,pp. : 7-7

MDPI

Access to resources Recommend Favorite

Fibrinolytic Factors in Liver Fibrosis

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 9, 2011-01 ,pp. : 1441-1446

Bentham Science Publishers

Access to resources Recommend Favorite

The Non-Genomic Effects of the PPAR#946;#947; Agonist GW0742 on Streptozotocin Treated Rat Aorta

By  

Current Molecular Pharmacology, Vol. 11, Iss. 2, 2018-04 ,pp. : 149-154

Bentham Science Publishers

Access to resources Recommend Favorite

Developing strategies for liver fibrosis treatment

By Murphy Frank   Arthur Michael   Iredale John  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1575-1585

Informa Healthcare

Access to resources Recommend Favorite

Liver Fibrosis: Possible Involvement of EMT

By  

Cells Tissues Organs, Vol. 185, Iss. 1-3, 2007-06 ,pp. : 213-221

Karger

Access to resources Recommend Favorite